Skip to main content
. Author manuscript; available in PMC: 2014 Mar 12.
Published in final edited form as: Clin Pharmacol Ther. 2012 Oct 3;92(5):575–583. doi: 10.1038/clpt.2012.137

Figure 5.

Figure 5

Schematic view of: left, effect of CYP3A5 genotype on ritonavir - atazanavir first pass effect; right, final linked ritonavir – atazanavir model. CYP3A5*3*3 are low expressors and CYP3A5*1*3, *1*1 are high expressors.